Immatics NV logo

Immatics NV

IMTX
Healthcare|Biotechnology|Germany
$9.68
-0.28 (-2.81%)
Tangible Book
$3.84

Analyst Estimates

annual
{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 45.77, 52.76, 115.49, 260.33, 498.14 ], "ebit_estimate": [ -298.2, -308.77, -286.36, -227.79, -107.98 ], "ebitda_estimate": [ -271.08, -300.28, -337.6, -331.01, -189.08 ], "net_income_estimate": [ -270.19, -293.42, -298.71, -217.17, -94.35 ], "per_share_eps_estimate": [ -1.98, -1.95, -1.71, -1.02, -0.22 ], "eps_nri_estimate": [ -1.98, -1.95, -1.71, -1.02, -0.22 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 4.69, 4.2, 2.41, 2.52, 2.35 ], "pretax_income_estimate": [ -270.53, -293.52, -298.71, -217.17, -94.35 ], "operating_cash_flow_per_share_estimate": [ -1.6, -1.17, -1.67, -1.15, 0.02 ], "roa_estimate": [ -39, -38.5, -47.1, -40.5, -5.7 ], "roe_estimate": [ -46.88, -43.3, -53.5, -50, -7.5 ], "gross_margin_estimate": [ 100, 75, 75.5, 76, 78.55 ], "operating_cash_flow_estimate": [ -215.24, -156.81, -224.45, -154.31, 3.12 ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "26.64", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 26.64, "future_ebit_estimate_growth": -10.48, "future_ebitda_estimate_growth": -19.36, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -9.88, "future_pretax_income_estimate_growth": -9.54, "future_book_value_per_share_estimate_growth": -16.17, "future_roa_estimate_growth": -12.98, "future_roe_estimate_growth": -8.78, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }
quarterly
{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 11.99, 11.39, 13.54, 4.57, 4.57, 4.57, 21.69 ], "ebit_estimate": [ -72.55, -75.17, -73.61, -79.36, -81.35, -83.35, -72.79 ], "ebitda_estimate": [ -73.21, -74.05, -66.26, null, null, null, null ], "net_income_estimate": [ -65.77, -68.95, -65.57, -75.07, -77.19, -79.36, -68.97 ], "per_share_eps_estimate": [ -0.49, -0.51, -0.48, -0.57, -0.59, -0.59, -0.52 ], "eps_nri_estimate": [ -0.49, -0.51, -0.48, -0.57, -0.59, -0.59, -0.52 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -65.51, -69.19, -67.11, -75.07, -77.19, -79.36, -68.97 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 100, 100, 100, 100, 100, 100, 75 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "26.64", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 26.64, "future_ebit_estimate_growth": -10.48, "future_ebitda_estimate_growth": -19.36, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -9.88, "future_pretax_income_estimate_growth": -9.54, "future_book_value_per_share_estimate_growth": -16.17, "future_roa_estimate_growth": -12.98, "future_roe_estimate_growth": -8.78, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }